FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to Nula-cel for Sickle Cell Disease

Kamau Therapeutics announced that the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to nula-cel, an investigational gene-corrected stem cell medicine for sickle cell disease. This designation is based on preliminary clinical evidence from the ongoing Phase 1/2 RESTORE trial, where all three treated patients achieved transfusion independence with no vaso-occlusive events. RMAT designation facilitates early and frequent FDA engagement, potentially leading to priority review and accelerated approval for therapies addressing unmet medical needs in serious conditions.